Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06596694 · ClinicalTrials.gov registry record · Phase 1

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

A Phase 1 study of Gastrointestinal Cancer, sponsored by Merck Sharp & Dohme.

Recruiting
Registry status
Phase 1
Development phase
180
Enrollment target
20
Study locations

NCT06596694 is a Phase 1 study of Gastrointestinal Cancer that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 180 participants, below the 230-participant average among 48 other Gastrointestinal Cancer trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06596694, a Phase 1 study of Gastrointestinal Cancer, is actively recruiting participants, sponsored by Merck Sharp & Dohme.

RECRUITING
Registry status
Phase 1
Development phase
180 participants
Enrollment target
20
Study locations

Study Summary

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment

Conditions Studied

Gastrointestinal Cancer

Interventions

  • BIOLOGICAL Patritumab deruxtecan

Study Locations (20)

Florida

  • University of Florida ( Site 1202) - Gainesville
  • Mount Sinai Medical Center Comprehensive Cancer Center ( Site 1213) - Miami Beach

New York

  • NYU Langone Hospital - Long Island ( Site 1230) - Mineola
  • Perlmutter NYU Cancer Center ( Site 1212) - New York

Victoria

  • Alfred Health ( Site 0102) - Melbourne
  • Austin Health ( Site 0103) - Melbourne

California

  • UCLA Hematology Oncology Santa Monica ( Site 1205) - Santa Monica

Colorado

  • University of Colorado Cancer Center ( Site 1200) - Aurora

District of Columbia

  • Sibley Memorial Hospital ( Site 1208) - Washington D.C.

Georgia

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 1203) - Marietta

Illinois

  • University of Chicago Medical Center ( Site 1204) - Chicago

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2024-11-03
Est. Completion 2028-12-07
Phase Phase 1

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06596694

The ClinicalTrials.gov registry entry for NCT06596694 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 230-participant average among 48 other Gastrointestinal Cancer trials with a reported enrollment target (22% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gastrointestinal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Patritumab deruxtecan is the first listed.

NCT06596694 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Florida, New York, Victoria.

Frequently Asked Questions

What is clinical trial NCT06596694 about?

NCT06596694 is a clinical study titled "Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)". Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patrit...

What is the current status of trial NCT06596694?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2024-11-03. Estimated completion is 2028-12-07.

What conditions does trial NCT06596694 study?

This clinical trial studies the following conditions: Gastrointestinal Cancer.

What interventions are being tested in trial NCT06596694?

The interventions under investigation include: Patritumab deruxtecan (BIOLOGICAL).

Who is sponsoring clinical trial NCT06596694?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06596694 being conducted?

This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastrointestinal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastrointestinal Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.